Approval For Access? Decoding The Significance Of China’s Opdivo Opening
First comes the approval, then market access. A rapid regulatory clearance for BMS’s Opdivo in China not only pioneers a new and potentially huge market for immuno-oncology treatments, but may potentially set an example in how to expand market access for many new therapies waiting to get into the country, amid multiple recent regulatory and policy changes.
You may also be interested in...
Innovative new drugs in five categories are now eligible for fast track approvals in China, with the timescale shortened from 18 months normally to six months under the expanded system.
China approves first immuno-oncology drug in the form of BMS’s Opdivo for lung cancer, opening up a new potentially huge market for the class, but much will depend on pricing and reimbursement policies.
The first ever agency devoted to medical insurance in China, MISA is potentially on track to become a major player in drug price negotiation, reimbursement level setting, and drug and device bidding in the country.